



April 10, 2021

<<MEMBER FIRST NAME>> <<MEMBER LAST NAME>>

<<ADDRESS>>

<<CITY>> <<STATE>> <<ZIP>>

Dear University of Arkansas System Member,

MedImpact Healthcare Systems, Inc., (MedImpact) on behalf of the University of Arkansas System Health Plan, will be implementing a change to the prescription benefit plan that affects you. **Please continue to read this entire letter.**

Effective August 01, 2021, LUMIGAN 0.01% EYE DROPS will no longer be covered under the prescription benefit plan. **You are receiving this letter because our records indicate you had a prescription filled for LUMIGAN 0.01% EYE DROPS within the last 120 days.**

The Plan will continue to cover your prescription for **LUMIGAN 0.01% EYE DROPS** until **August 01, 2021**. Please use this time between now and **August 01, 2021** to discuss alternative medications with your doctor. You may be able to switch a comparable medication used to treat your condition – including formulary covered alternatives such as **Lantanoprost**.

If your doctor determines that the formulary alternative covered medication is not right for you due to your medical condition, an appeal process for coverage of a medication not on the formulary is available. To request coverage, your doctor must submit the appeal form and required medical documentation to EBRx by fax to 1-877-540-9036.

Pharmacy benefits are subject to terms, conditions and eligibility as outlined in the benefit documentation in effect at the time services are provided. The above change to your prescription benefit plan is directed by the University's Pharmacy Advisory Committee.

For questions, please contact MedImpact Healthcare Systems, Inc. at 1-800-788-2949.

Sincerely,

MedImpact and the University of Arkansas Pharmacy Advisory Committee

The University of Arkansas System's' prescription drug formulary, administered by MedImpact, is maintained by the University of Arkansas System's Pharmacy Advisory Committee. The Pharmacy Advisory Committee is composed of both faculty and clinical pharmacists, who advise the Committee on the most recent medical research results. The recommendations by the committee are based on the latest available evidence-based studies.